ZA953629B - Soluble polypeptidic fragments of lag-3 protein method of production thereof therapeutic composition anti-idiotype antibodies - Google Patents
Soluble polypeptidic fragments of lag-3 protein method of production thereof therapeutic composition anti-idiotype antibodiesInfo
- Publication number
- ZA953629B ZA953629B ZA953629A ZA953629A ZA953629B ZA 953629 B ZA953629 B ZA 953629B ZA 953629 A ZA953629 A ZA 953629A ZA 953629 A ZA953629 A ZA 953629A ZA 953629 B ZA953629 B ZA 953629B
- Authority
- ZA
- South Africa
- Prior art keywords
- lag
- soluble
- production
- therapeutic composition
- idiotype antibodies
- Prior art date
Links
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 title 1
- 230000003302 anti-idiotype Effects 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 238000001814 protein method Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102000017578 LAG3 Human genes 0.000 abstract 2
- 101150030213 Lag3 gene Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108020001580 protein domains Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9405643 | 1994-05-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA953629B true ZA953629B (en) | 1996-11-05 |
Family
ID=9463004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA953629A ZA953629B (en) | 1994-05-06 | 1995-05-05 | Soluble polypeptidic fragments of lag-3 protein method of production thereof therapeutic composition anti-idiotype antibodies |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US5955300A (xx) |
| EP (1) | EP0758383B1 (xx) |
| JP (1) | JP3700859B2 (xx) |
| KR (1) | KR100257466B1 (xx) |
| CN (1) | CN1110557C (xx) |
| AT (1) | ATE352617T1 (xx) |
| BR (1) | BR9507618A (xx) |
| CA (1) | CA2189657C (xx) |
| DE (1) | DE69535375T2 (xx) |
| DK (1) | DK0758383T3 (xx) |
| ES (1) | ES2281899T3 (xx) |
| IL (1) | IL113617A (xx) |
| MX (1) | MX9605365A (xx) |
| NO (1) | NO325828B1 (xx) |
| PT (1) | PT758383E (xx) |
| RU (1) | RU2178306C2 (xx) |
| WO (1) | WO1995030750A2 (xx) |
| ZA (1) | ZA953629B (xx) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2186797T3 (es) | 1995-07-21 | 2003-05-16 | Applied Research Systems | Metodo para detectar, identificar, aislar y marcar selectivamente, y direccionar linfocitos th1 por medio de la proteina lag-3. |
| JP2000516101A (ja) * | 1996-11-28 | 2000-12-05 | アンスティテュ ギュスタブ ルシ | Ｌａｇ−３タンパク質の変異体、その発現及び使用 |
| CA2272130C (en) | 1996-11-29 | 2007-10-23 | Applied Research Systems Ars Holding N.V. | Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3) |
| EP0900841A1 (en) * | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | LAG-3 splice variants |
| EP0893507A1 (en) * | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
| US6660843B1 (en) † | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6434012B2 (en) * | 2000-02-11 | 2002-08-13 | Tyco Electronics Logistics Ag | Circuit board interconnect |
| EP1278778A2 (en) * | 2000-05-03 | 2003-01-29 | Amgen Inc., | Modified peptides, comprising an fc domain, as therapeutic agents |
| JP2005535290A (ja) * | 2002-02-22 | 2005-11-24 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための組成物と方法 |
| ES2439580T3 (es) | 2003-02-28 | 2014-01-23 | The Johns Hopkins University | Regulación de células T |
| FR2868781B1 (fr) * | 2004-04-13 | 2008-02-22 | Immutep | Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| DK3508502T5 (da) | 2013-09-20 | 2024-09-02 | Bristol Myers Squibb Co | Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| SI3116909T1 (sl) | 2014-03-14 | 2020-03-31 | Novartis Ag | Molekule protiteles na LAG-3 in njih uporaba |
| KR102433464B1 (ko) | 2014-05-28 | 2022-08-17 | 아게누스 인코포레이티드 | 항-gitr 항체 및 이의 사용 방법 |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| US10786547B2 (en) | 2015-07-16 | 2020-09-29 | Biokine Therapeutics Ltd. | Compositions, articles of manufacture and methods for treating cancer |
| SG10201906059VA (en) | 2015-07-30 | 2019-08-27 | Macrogenics Inc | Pd-1-binding molecules and methods of use thereof |
| WO2017025871A1 (en) | 2015-08-07 | 2017-02-16 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy comprising anti ctla-4 antibodies |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| BR112018010158A2 (pt) | 2015-11-20 | 2018-11-21 | Regeneron Pharma | roedor, polipeptídeo lag-3 humanizado, célula ou tecido, célula-tronco embrionária e embrião de roedor, métodos para produzir um roedor, para avaliar a eficácia antitumoral e as propriedades farmacocinéticas de uma droga |
| US11447557B2 (en) | 2015-12-02 | 2022-09-20 | Agenus Inc. | Antibodies and methods of use thereof |
| EP3389714A4 (en) | 2015-12-14 | 2019-11-13 | MacroGenics, Inc. | BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY TO PD-1 AND CTLA-4 AND METHODS OF USE |
| WO2017106129A1 (en) | 2015-12-16 | 2017-06-22 | Merck Sharp & Dohme Corp. | Anti-lag3 antibodies and antigen-binding fragments |
| AU2017213633B2 (en) * | 2016-02-04 | 2023-08-03 | Trianni, Inc. | Enhanced production of immunoglobulins |
| WO2017220990A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 antibodies |
| PL3476399T3 (pl) | 2016-06-23 | 2022-06-20 | Jiangsu Hengrui Medicine Co. Ltd. | Przeciwciało lag-3, jego fragment wiążący i jego zastosowanie farmaceutyczne |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| EA201990912A1 (ru) | 2016-10-13 | 2019-10-31 | Анти-lag-3 антитела и их композиции | |
| TW201829462A (zh) | 2016-11-02 | 2018-08-16 | 英商葛蘭素史克智慧財產（第二）有限公司 | 結合蛋白 |
| IL268667B1 (en) | 2017-02-10 | 2024-08-01 | Regeneron Pharma | Radiolabeled antibodies against LAG3 for immuno-PET imaging |
| JP2020513009A (ja) | 2017-04-05 | 2020-04-30 | シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ | Ｐｄ−１、ｔｉｍ−３、およびｌａｇ−３を標的とする併用治療 |
| EP3621642B1 (en) * | 2017-05-10 | 2024-09-18 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Human monoclonal antibodies against lag3 and uses thereof |
| CN118356488A (zh) | 2017-05-30 | 2024-07-19 | 百时美施贵宝公司 | 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物 |
| HUE065242T2 (hu) | 2017-05-30 | 2024-05-28 | Bristol Myers Squibb Co | LAG-3-pozitív tumorok kezelése |
| AU2018323955A1 (en) | 2017-08-30 | 2020-03-19 | Phanes Therapeutics, Inc. | Anti-LAG-3 antibodies and uses thereof |
| TW201927337A (zh) | 2017-12-22 | 2019-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種ｌａｇ－３抗體醫藥組成物及其用途 |
| MA55965A (fr) | 2019-05-13 | 2022-03-23 | Regeneron Pharma | Combinaison d'inhibiteurs pd-1 et d'inhibiteurs lag-3 pour une efficacité améliorée dans le traitement du cancer |
| CN115340606B (zh) * | 2019-05-31 | 2023-12-19 | 瑞阳(苏州)生物科技有限公司 | 与人lag-3蛋白结合的抗体及其编码基因和应用 |
| CN110950966B (zh) * | 2019-12-13 | 2020-12-11 | 启辰生生物科技(珠海)有限公司 | 融合蛋白、编码核酸和细胞及用途 |
| WO2024192033A1 (en) | 2023-03-13 | 2024-09-19 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2092468T3 (es) | 1988-01-22 | 1996-12-01 | Zymogenetics Inc | Metodos para producir analogos de receptores secretados. |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| FR2656800B1 (fr) | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
| US5976877A (en) | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
| WO1992000092A1 (en) * | 1990-07-02 | 1992-01-09 | Bristol-Myers Squibb Company | Ligand for cd28 receptor on b cells and methods |
-
1995
- 1995-05-05 PT PT95920125T patent/PT758383E/pt unknown
- 1995-05-05 JP JP52872995A patent/JP3700859B2/ja not_active Expired - Lifetime
- 1995-05-05 IL IL113617A patent/IL113617A/en not_active IP Right Cessation
- 1995-05-05 AT AT95920125T patent/ATE352617T1/de active
- 1995-05-05 US US08/737,271 patent/US5955300A/en not_active Ceased
- 1995-05-05 BR BR9507618A patent/BR9507618A/pt not_active IP Right Cessation
- 1995-05-05 CA CA002189657A patent/CA2189657C/fr not_active Expired - Lifetime
- 1995-05-05 DK DK95920125T patent/DK0758383T3/da active
- 1995-05-05 ZA ZA953629A patent/ZA953629B/xx unknown
- 1995-05-05 KR KR1019960706281A patent/KR100257466B1/ko not_active IP Right Cessation
- 1995-05-05 EP EP95920125A patent/EP0758383B1/fr not_active Expired - Lifetime
- 1995-05-05 CN CN95193718A patent/CN1110557C/zh not_active Expired - Lifetime
- 1995-05-05 WO PCT/FR1995/000593 patent/WO1995030750A2/fr active IP Right Grant
- 1995-05-05 ES ES95920125T patent/ES2281899T3/es not_active Expired - Lifetime
- 1995-05-05 RU RU96123299/14A patent/RU2178306C2/ru active
- 1995-05-05 DE DE69535375T patent/DE69535375T2/de not_active Expired - Lifetime
- 1995-05-05 US US09/931,103 patent/USRE38313E1/en not_active Expired - Lifetime
- 1995-05-05 MX MX9605365A patent/MX9605365A/es active IP Right Grant
-
1996
- 1996-11-04 NO NO19964650A patent/NO325828B1/no not_active IP Right Cessation
-
1998
- 1998-04-13 US US09/058,555 patent/US6143273A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US6143273A (en) | 2000-11-07 |
| DK0758383T3 (da) | 2007-05-29 |
| IL113617A (en) | 2007-09-20 |
| NO325828B1 (no) | 2008-07-28 |
| CA2189657C (fr) | 2002-03-12 |
| MX9605365A (es) | 1997-12-31 |
| DE69535375D1 (de) | 2007-03-15 |
| ES2281899T3 (es) | 2007-10-01 |
| DE69535375T2 (de) | 2007-11-08 |
| NO964650L (no) | 1997-01-06 |
| NO964650D0 (no) | 1996-11-04 |
| US5955300A (en) | 1999-09-21 |
| KR970702917A (ko) | 1997-06-10 |
| RU2178306C2 (ru) | 2002-01-20 |
| AU708825B2 (en) | 1999-08-12 |
| WO1995030750A2 (fr) | 1995-11-16 |
| PT758383E (pt) | 2007-05-31 |
| CA2189657A1 (fr) | 1995-11-16 |
| CN1155904A (zh) | 1997-07-30 |
| JP3700859B2 (ja) | 2005-09-28 |
| ATE352617T1 (de) | 2007-02-15 |
| EP0758383B1 (fr) | 2007-01-24 |
| IL113617A0 (en) | 1995-08-31 |
| EP0758383A1 (fr) | 1997-02-19 |
| JPH09508023A (ja) | 1997-08-19 |
| BR9507618A (pt) | 1997-08-19 |
| CN1110557C (zh) | 2003-06-04 |
| AU2570195A (en) | 1995-11-29 |
| WO1995030750A8 (fr) | 1999-07-29 |
| WO1995030750A3 (fr) | 1995-12-21 |
| KR100257466B1 (ko) | 2000-07-01 |
| USRE38313E1 (en) | 2003-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA953629B (en) | Soluble polypeptidic fragments of lag-3 protein method of production thereof therapeutic composition anti-idiotype antibodies | |
| BG102983A (en) | Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application | |
| NZ500253A (en) | Osteoprotegerin binding proteins and receptors | |
| WO1996017924A3 (en) | Novel hedgehog-derived polypeptides | |
| AU7565991A (en) | Variant cd44 surface proteins, dna sequences coding them, antibodies against these proteins and their use in diagnosis and therapy | |
| HK1030551A1 (en) | Antimicrobial peptides | |
| DE69926627D1 (de) | Insulinartigen wachstumsfaktor bindendes protein -3 variante | |
| AU7017494A (en) | Purified mammalian flt3 ligands and agonists and antagonists thereof | |
| EP0161007A3 (en) | Retro - inverso c-terminal hexapeptide analogues of substance p | |
| AU5508396A (en) | Pcna binding substance | |
| EP1132402A4 (en) | PEPTIDE FRAGMENTS WITH CELL DEATH PREVENTIVE ACTIVITY | |
| DE69333952D1 (de) | Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen. | |
| AU2676399A (en) | Novel cystine knot protein and materials and methods for making it | |
| GB9416536D0 (en) | Orphan receptor | |
| GB2357507A (en) | Peptide fragments of cholera toxin B or enterotoxin B as vaccine adjuvants | |
| DE69623803D1 (de) | Verwendung von KASEINFRAGMENTEn als WACHSTUMERFÖRDERer | |
| DE59813388D1 (de) | Polypeptide mit Aminosäuresequenzen aus dem N-terminalen Bereich von gp116 von Cytomegalovirus und deren Verwendung bei der Diagnostik, Prophylaxe und Therapie | |
| HU9601298D0 (en) | Endothelin-converting enzyme | |
| NZ606260A (en) | Novel polypeptides involved in immune response |